Core Viewpoint - Jin Cheng Pharmaceutical reported a revenue of 1.932 billion and a net profit of 31.577 million for the first three quarters of 2025, highlighting short-term performance pressure due to industry conditions but showcasing improvements in financial structure, core business breakthroughs, and increased institutional recognition, indicating the long-term value of strategic layout is gradually emerging [1][2]. Financial Performance - The company achieved a revenue of 1.932 billion and a net profit of 31.577 million in the first three quarters of 2025 [1]. - The asset-liability ratio decreased to 27.69% by the end of the third quarter, down from 31.63% at the end of 2024, marking a significant decline of 3.94 percentage points [1]. Shareholder Structure - The investment value of the company has been highly recognized by professional institutions, with new entries from national social security funds in the top ten circulating shareholders, indicating market confidence in the company's long-term development logic [1]. Strategic Business Development - The company has focused on high-end pharmaceutical chemicals, synthetic biology, women's health technology, and high-end anti-infection fields, forming a strategic development layout supported by five major areas [2]. - Jin Cheng Pharmaceutical has actively participated in various provincial and national centralized procurement efforts, leading to significant sales growth in its biological and specialty raw materials segment [2]. Research and Development Achievements - The company has accelerated the transformation of R&D results, with multiple product registrations and certifications both domestically and internationally, including the approval of various formulations and raw materials [3]. - Jin Cheng Pharmaceutical plans to continue focusing on the five major areas of "pharmaceutical chemicals, synthetic biology, women's health technology, high-end anti-infection, and new tobacco," aiming to enhance business boundaries and increase industry added value [3].

Core Insights - The article highlights the recent movements of social security funds in the stock market, revealing that 43 new stocks were added to their portfolio in the third quarter [1] - A total of 1,315 companies have released their third-quarter reports, with social security funds appearing in 156 stocks, indicating significant institutional activity [1] Summary by Category New Investments - Social security funds initiated positions in 43 new stocks during the third quarter [1] - Among the new stocks, the highest holdings were in Jin Cheng Pharmaceutical (11.89 million shares), Kesi Da (10.52 million shares), and Huazheng New Materials (3.70 million shares) [1] - The stock with the highest proportion held by social security funds is Jin Cheng Pharmaceutical, accounting for 3.20% of its circulating shares [2] Performance Metrics - In terms of performance, 30 of the newly invested stocks reported year-on-year net profit growth, with Huazheng New Materials showing the highest increase of 1,042.19% [2] - The average increase of the newly invested stocks since October is 0.96%, which underperformed compared to the Shanghai Composite Index [2] - The best-performing stock among the new investments is Beifang Changlong, with a cumulative increase of 28.05% [2] Holdings Overview - A detailed list of stocks newly invested by social security funds includes Jin Cheng Pharmaceutical, Yi Yi Co., Huazheng New Materials, and others, with varying levels of holdings and industry classifications [2][3] - Notable holdings include Jiangsu Jinzu (45.65 million shares) and Fangzheng Technology (30.13 million shares), indicating a diverse investment strategy across different sectors [3]

Group 1 - The core viewpoint of the news is that Jincheng Pharmaceutical (300233.SZ) has seen an increase in institutional investor holdings, with a total of 1.13 billion shares held by 9 institutions, representing 29.44% of the total share capital, which is an increase of 4.77 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, 2 new public funds disclosed their holdings in Jincheng Pharmaceutical this quarter, including the Fuguo Precision Medical Flexible Allocation Mixed Fund and the Xingquan Light Asset Mixed Fund (LOF) [1] - A total of 14 public funds were not disclosed this quarter, including major funds such as Dachen Jingheng Mixed A and Dachen Zhuoxiang One-Year Holding Mixed A [1] Group 3 - For social security funds, 2 new social security funds disclosed their holdings in Jincheng Pharmaceutical, namely the National Social Security Fund 502 Portfolio and the National Social Security Fund 601 Portfolio [2] - In terms of foreign investment, one foreign fund, Hong Kong Central Clearing Limited, reduced its holdings by 0.56% compared to the previous quarter [2]

Group 1 - Shuyou Shen plans to raise no more than 1.253 billion yuan through a private placement to support innovative drug research and supplement working capital [1] - The issuance will involve no more than 143 million shares, with the price set at no less than 80% of the average trading price over the previous 20 trading days [1] Group 2 - WuXi AppTec reported a 84.84% year-on-year increase in net profit for the first three quarters, reaching 12.076 billion yuan, driven by a focus on CRDMO business and gains from selling shares in WuXi XDC Cayman Inc. [2] - The company achieved a revenue of 32.857 billion yuan, marking an 18.61% year-on-year growth [2] Group 3 - Wanfu Bio's net profit for the first three quarters decreased by nearly 70%, with a revenue of 1.69 billion yuan, down 22.52% year-on-year [3] - The third quarter revenue was 445 million yuan, a decline of 26.66% [3] Group 4 - Jincheng Pharmaceutical reported a 79.1% year-on-year decrease in net profit for the first three quarters, totaling 31.58 million yuan, with a revenue of 1.932 billion yuan, down 23.19% [4] - The third quarter revenue was 572 million yuan, a decline of 24.44% [4] Group 5 - WuXi AppTec plans to transfer 100% equity of two subsidiaries for a base price of 2.8 billion yuan, aiming to reinvest the funds into core business areas [5] - The sale of non-core assets is expected to enhance the company's competitiveness and potentially provide a short-term boost to stock prices [5]

Group 1 - Jincheng Pharmaceutical (SZ 300233) announced on October 26 that its 17th meeting of the 6th board of directors was held on October 23, 2025, to review proposals including the revision and establishment of certain corporate governance systems [1] - For the year 2024, Jincheng Pharmaceutical's revenue composition is 100% from the pharmaceutical manufacturing industry [1] - As of the report date, Jincheng Pharmaceutical has a market capitalization of 6.6 billion yuan [1]

山东金城医药集团股份有限公司 信息披露管理制度 山东金城医药集团股份有限公司 信息披露管理制度 第一章 总 则 第一条 为加强山东金城医药集团股份有限公司（以下简称"公司"或"本公 司"）信息披露工作管理，规范信息披露行为，维护公司、投资者及其他利益相 关者的合法权益，根据《中华人民共和国公司法》《中华人民共和国证券法》（以 下简称"《证券法》"）《上市公司信息披露管理办法》《深圳证券交易所创业 板股票上市规则》《深圳证券交易所创业板上市公司自律监管指引第 2 号—创业 板上市公司规范运作》《深圳证券交易所上市公司自律监管指引第 5 号—信息披 露事务管理》以及《山东金城医药集团股份有限公司章程》（以下简称"《公司 章程》"）等有关规定，并结合公司实际情况，制定本制度。 第二条 本制度所称"信息"是指根据法律法规和深圳证券交易所（以下简称 "深交所"）相关规则应当披露的，可能对公司股票及其衍生品种交易价格或投 资决策产生较大影响的信息以及证券监管部门要求披露的信息，或者公司主动披 露的信息。 本制度所称的"披露"是指公司及相关信息披露义务人在规定的时间内、在 规定的媒体上、以规定的方式向社会公布上述定义的信息 ...

山东金城医药集团股份有限公司 总裁工作细则 山东金城医药集团股份有限公司 总裁工作细则 第一章 总则 第一条 为完善山东金城医药集团股份有限公司（以下简称"公司"）法人治 理结构，规范经营层行为，确保公司生产经营管理工作的顺利进行，根据《中华 人民共和国公司法》《中华人民共和国证券法》《上市公司治理准则》《深圳证 券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号 —创业板上市公司规范运作》等相关有关法律、行政法规、规范性文件及《山东 金城医药集团股份有限公司章程》（以下简称"《公司章程》"）的规定，制定 本细则。 第二条 本细则所称总裁及高级管理人员是指公司总裁、副总裁、财务负责人 和董事会秘书。 第二章 总裁的聘任和解聘 第三条 公司设总裁一名，由董事长提名，董事会聘任或解聘。公司设副总裁 若干名，由董事会根据总裁的推荐予以聘任或解聘。 董事可受聘兼任总裁、副总裁、财务负责人和董事会秘书。 第四条 总裁及其他高级管理人员每届任期三年，期限届满后连聘可以连任。 第五条 总裁及其他高级管理人员可以在任期届满以前提出辞职。 第三章 总裁办公会议制度 第六条 公司实行总裁负责下的总裁办公会 ...

第四条 独立董事原则上最多在三家境内上市公司担任独立董事，并应当确 保有足够的时间和精力有效地履行独立董事的职责。公司独立董事及拟担任公司 独立董事的人士应当按照中国证券监督管理委员会（以下简称"中国证监会"） 的要求，参加中国证监会及其授权机构所组织的培训。 第五条 公司独立董事占董事会成员的比例不得低于三分之一，且至少包括 一名会计专业人士。 山东金城医药集团股份有限公司 独立董事制度 山东金城医药集团股份有限公司 独立董事制度 第一章 总则 第一条 为完善山东金城医药集团股份有限公司（以下简称"公司"）治理 结构，充分发挥独立董事在公司治理中的作用，保障全体股东、特别是中小股东 的合法权益不受侵害，依据《中华人民共和国公司法》《中华人民共和国证券法》 《上市公司独立董事管理办法》《深圳证券交易所上市公司自律监管指引第 2 号 —创业板上市公司规范运作》（以下简称"《创业板上市公司规范运作指引》"） 《上市公司治理准则》等有关法律、法规和《山东金城医药集团股份有限公司章 程》（以下简称"《公司章程》"）等有关规定，制订本制度。 第二条 独立董事是指不在公司担任除董事外的其他职务，并与公司及公司 主要股东、 ...

山东金城医药集团股份有限公司 投资者关系管理制度 山东金城医药集团股份有限公司 第一条 为规范公司投资者关系管理工作，加强公司与投资者之间的有效沟通，促 进公司完善治理，提高公司质量，切实保护投资者特别是中小投资者合法权益，根据《中 华人民共和国公司法》《上市公司治理准则》《上市公司与投资者关系管理工作指引》 《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号—创业板上市公司规范运作》等相关法律、行政法规、规范性文件及《山东金城医药 集团股份有限公司章程》（以下简称"《公司章程》"）的规定，结合本公司实际情况， 制定本制度。 投资者关系管理制度 第一章 总则 （二）平等性原则：公司开展投资者关系管理活动，应当平等对待所有投资者，尤 第二条 投资者关系管理是指公司通过便利股东权利行使、信息披露、互动交流和 诉求处理等工作，加强与投资者之间的沟通，增进投资者对公司的了解和认同，提高 公司治理水平和企业整体价值，实现尊重投资者、回报投资者、保护投资者目的的相 关活动。 第三条 投资者关系管理的目的： （一）促进公司与投资者之间的良性关系，增进投资者对公司的了解，通过充分的 信息披露加 ...

山东金城医药集团股份有限公司 董事和高级管理人员所持公司股份及其变动管理制度 山东金城医药集团股份有限公司 董事和高级管理人员所持公司股份及其变动 管理制度 第一章 总 则 第二条 本制度适用于公司董事和高级管理人员以及本制度第九条规定的自然 人、法人或其他组织所持公司股份及其变动的管理。 第三条 本制度所指高级管理人员指公司总裁、副总裁、财务负责人和董事会 秘书。 第四条 本公司董事和高级管理人员在买卖公司股票及其衍生品种前，应知悉 《公司法》《证券法》等法律、行政法规、规范性文件关于内幕交易、操纵市场、 短线交易等禁止行为的规定，不得进行违法违规的交易。 第二章 股票买卖禁止行为 第五条 公司董事和高级管理人员所持本公司股份在下列情形之一的，不得转 让本公司股份： 第一条 为加强山东金城医药集团股份有限公司（以下简称"公司"）对董事 和高级管理人员持有及买卖本公司股份的管理工作，维护证券市场秩序，根据《中 华人民共和国公司法》（以下简称"《公司法》"）《中华人民共和国证券法》（以 下简称"《证券法》"）《上市公司董事和高级管理人员所持本公司股份及其变动 管理规则》《上市公司股东减持股份管理暂行办法》《深圳 ...